DEFA14A: Avadel-Alkermes Merger Clears HSR Hurdle

Avadel Pharmaceuticals announced the expiration of the HSR Act waiting period, satisfying a key condition for its acquisition by Alkermes.

Summary

• Avadel Pharmaceuticals PLC announced the expiration of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) waiting period at 11:59 p.m. on December 8, 2025.
• This expiration satisfies one of the conditions for the previously announced acquisition of Avadel by Alkermes PLC.
• The acquisition is structured as a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland, pursuant to a Transaction Agreement dated October 22, 2025, and amended on November 18, 2025.
• The closing of the acquisition remains subject to other customary conditions, including approval from Avadel's shareholders and sanction by the Irish High Court.
• A definitive proxy statement, including the Scheme Document, was filed with the SEC on December 3, 2025, and sent to shareholders as of the November 25, 2025 record date.

Sentiment

Score: 7

Explanation: The expiration of the HSR waiting period is a positive step towards completing the acquisition, reducing regulatory uncertainty. However, other significant conditions, such as shareholder and court approvals, still remain, introducing some residual risk.

Positives

• Expiration of the HSR Act waiting period removes a significant regulatory hurdle for the acquisition, moving the transaction closer to completion.

Risks

• The ability of the parties to consummate the Acquisition in a timely manner or at all.
• The satisfaction (or waiver) of conditions to the consummation of the Acquisition, including with respect to the approval of Avadel shareholders.
• The possibility that more competing offers for Avadel may be made.
• Potential delays in consummating the Acquisition.
• The ability of Avadel to timely and successfully achieve the anticipated benefits of the Acquisition.
• The impact of health pandemics on the parties' respective businesses and the actions the parties may take in response thereto.
• The occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Transaction Agreement.
• The effect of the announcement or pendency of the Acquisition on Avadel's business relationships, operating results and business generally.
• Costs related to the Acquisition.
• The outcome of any legal proceedings that may be instituted against the parties or any of their respective directors or officers related to the Transaction Agreement or the Acquisition.

Future Outlook

The acquisition is progressing, with the HSR Act condition now satisfied. However, the closing remains contingent on Avadel shareholder approval and Irish High Court sanction. The company acknowledges various risks that could impact the timely consummation and anticipated benefits of the acquisition.

Management Comments

• The directors of Avadel accept responsibility for the information contained in this report. To the best of the knowledge and belief of the directors of Avadel (who have taken all reasonable care to ensure such is the case), the information contained in this report is in accordance with the facts and does not omit anything likely to affect the import of such information.

Industry Context

This acquisition reflects ongoing consolidation within the pharmaceutical and biotechnology sectors, where larger companies often acquire smaller, specialized firms to expand their product pipelines or market share. Regulatory clearances like the HSR Act are standard milestones in such transactions, indicating progress towards deal completion.

Comparison to Industry Standards

• The expiration of the HSR Act waiting period is a standard regulatory step in U.S. mergers and acquisitions, comparable to similar clearances seen in other large pharmaceutical deals, such as the AbbVie acquisition of Allergan or Bristol Myers Squibb's acquisition of Celgene.
• The use of an Irish scheme of arrangement is common for Irish-domiciled companies involved in cross-border M&A, similar to how Shire was acquired by Takeda or Allergan by Actavis.

Legal Proceedings

• The forward-looking statements section mentions the risk of 'the outcome of any legal proceedings that may be instituted against the parties or any of their respective directors or officers related to the Transaction Agreement or the Acquisition'.

Stakeholder Impact

• Shareholders: Will vote on the acquisition and are urged to read the Definitive Proxy Statement. Their shares will be acquired by Alkermes if the transaction closes.
• Employees: The effect of the announcement or pendency of the Acquisition on Avadel's business relationships and operations generally is noted as a risk, which could indirectly impact employees.

Next Steps

• Obtain approval of Avadel's shareholders for the acquisition.
• Secure sanction by the Irish High Court of the Scheme of Arrangement.
• Deliver the court order to the Irish Registrar of Companies.
• Shareholders are urged to read the Definitive Proxy Statement for voting decisions.

Key Dates

Recommendation

The HSR clearance is a positive step, reducing regulatory risk for the acquisition. However, the deal is not yet closed, with shareholder and Irish High Court approvals still pending. For existing shareholders, holding until the deal's completion or until further clarity on the remaining conditions emerges is prudent, as the HSR clearance largely de-risks one major aspect but doesn't guarantee closing. For new investors, the remaining conditions and potential for competing offers or termination still present a degree of uncertainty, making a 'hold' more appropriate than a 'buy' or 'sell' at this specific juncture, assuming the current market price already reflects much of the acquisition premium.

Keywords

Avadel Pharmaceuticals, Alkermes, Acquisition, Merger, HSR Act, Scheme of Arrangement, SEC Filing, Corporate Governance, Pharmaceuticals, Biotech